Dimensional Fund Advisors LP Purchases New Position in Mural Oncology plc (NASDAQ:MURA)

Dimensional Fund Advisors LP purchased a new stake in Mural Oncology plc (NASDAQ:MURA) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 22,563 shares of the company’s stock, valued at approximately $71,000. Dimensional Fund Advisors LP owned approximately 0.13% of Mural Oncology as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Acadian Asset Management LLC acquired a new stake in Mural Oncology in the 2nd quarter worth about $998,000. Rhumbline Advisers acquired a new stake in Mural Oncology in the 2nd quarter worth about $34,000. Harbor Capital Advisors Inc. acquired a new stake in Mural Oncology in the 2nd quarter worth about $115,000. Nicollet Investment Management Inc. acquired a new position in shares of Mural Oncology during the 2nd quarter worth approximately $308,000. Finally, BBR Partners LLC acquired a new position in shares of Mural Oncology during the 2nd quarter worth approximately $31,000. Hedge funds and other institutional investors own 80.21% of the company’s stock.

Wall Street Analyst Weigh In

MURA has been the topic of several recent research reports. Rodman & Renshaw initiated coverage on Mural Oncology in a report on Friday, June 28th. They set a “buy” rating and a $15.00 target price on the stock. Raymond James initiated coverage on Mural Oncology in a report on Friday, October 4th. They set a “strong-buy” rating and a $18.00 target price on the stock.

Mural Oncology Price Performance

NASDAQ:MURA opened at $3.45 on Wednesday. The firm has a market capitalization of $58.39 million and a PE ratio of -0.33. The business’s fifty day moving average price is $3.26 and its 200 day moving average price is $3.46. Mural Oncology plc has a 12 month low of $2.88 and a 12 month high of $17.00.

Mural Oncology (NASDAQ:MURA) last announced its earnings results on Tuesday, August 13th. The company reported ($1.86) earnings per share for the quarter, topping the consensus estimate of ($1.90) by $0.04. As a group, equities analysts anticipate that Mural Oncology plc will post -7.47 EPS for the current year.

Mural Oncology Company Profile

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.